Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.
Latest price
$44.15
-0.65%
Alpha Vantage · 11/6/2026
Adjusted daily closes · 252 observations · as of Nov 6, 2026
1 month
+9.7%
3 months
+6.4%
6 months
-4.2%
1 year
+6.0%
Year to date
+8.6%
52-week range
$38.74 – $48.43
Latest reported period: Sep 30, 2026
Market cap
$21.18B
P/E
22.4
P/B
2.2
P/S
3
Revenue
$6.96B
Net income
$939.9M
Diluted EPS
1.95
Gross margin
77.70%
Net margin
13.60%
Return on equity
9.90%
Total debt
$18.26B
Cash
$82.8M
Free cash flow
-$678.4M
Reported quarterly values, newest first
| Period | Revenue | Net income | Gross margin | Net margin | Free cash flow |
|---|---|---|---|---|---|
| Sep 30, 2026 | $1.35B | $129.5M | 84.60% | 9.60% | -$482.7M |
| Jun 30, 2026 | $1.34B | $45.5M | 85.60% | 3.40% | -$417M |
| Mar 31, 2026 | $2.36B | $507.1M | 71.70% | 21.60% | -$362.9M |
| Dec 31, 2025 | $1.9B | $257.8M | 74.70% | 13.50% | $584.2M |
| Sep 30, 2025 | $1.27B | $94.7M | 84.80% | 7.40% | -$306.3M |
| Jun 30, 2025 | $1.28B | $102.2M | 79.60% | 8.00% | -$566.6M |
| Mar 31, 2025 | $2.18B | $474.8M | 70.30% | 21.70% | -$505.1M |
| Dec 31, 2024 | $1.59B | $223.9M | 76.30% | 14.10% | $229.6M |
Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.
hour agoJohn CampbellEconomics and business editor, BBC News NIGetty ImagesThe average growth rate of the Northern Ireland economy would have to more than double to make Irish unification economically...
Original sourceThis article announces the filing of Form 144 for NISOURCE INC. on November 6. Form 144 is a notice of the intent to sell restricted securities, indicating potential insider transactions or sales by affiliates. The brief announcement provides no further details regarding the specifics of the filing.
Original sourceANI Pharmaceuticals has made a public offer to acquire Egetis Therapeutics for approximately SEK 5.6 billion ($560 million). The acquisition aims to expand ANI's rare disease business by adding EMCITATE, an approved treatment for MCT8 deficiency, which ANI estimates could achieve peak sales of over $300 million with patent protection extending into mid-2045. Egetis's board unanimously recommends the offer, and shareholders representing about 42% of outstanding shares have committed to accept, with the deal contingent on 90% shareholder acceptance and regulatory approvals.
Original sourceANI Pharmaceuticals has announced a recommended public offer to acquire Egetis Therapeutics AB for approximately $560 million. This acquisition aims to expand ANI's rare disease business, leveraging Egetis's lead asset, EMCITATE®, an approved treatment for MCT8 deficiency with an estimated peak sales potential of over $300 million. The deal is unanimously recommended by Egetis's Board and supported by shareholders controlling 42% of its shares.
Original source